# Persistence of Immunity Against Hepatitis B in 12-13 Year Old Adolescents After Infant Hepatitis B Vaccination

> **NCT00984139** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 306 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **BIOLOGICAL:** Engerix™-B Kinder

## Key facts

- **NCT ID:** NCT00984139
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10-12
- **Primary completion:** 2010-04-07
- **Final completion:** 2010-04-07
- **Target enrollment:** 306 (ACTUAL)
- **Last updated:** 2018-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00984139

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00984139, "Persistence of Immunity Against Hepatitis B in 12-13 Year Old Adolescents After Infant Hepatitis B Vaccination". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00984139. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*